REGENXBIO Inc. (RGNX) has 7 SEC Form 4 insider filings on record in the last 90 days. That includes 1 insider purchase totalling $949K, and 2 sales totalling $1.1M. Most recent filing: Sept. 3, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 3, 2026 filed Sept. 1, 2026 | Malzahn Craig Chief Technology Officer | $2,181 | 234 | −0% | No | |
|
|
||||||
| Aug. 27, 2026 filed Aug. 25, 2026 | Ciongoli Gregory Austin Director | +$949,381 | 187,644 | New | No | |
|
|
||||||
| Aug. 4, 2026 filed Aug. 1, 2026 | PAKOLA STEVE Chief Medical Officer | $72,365 | 7,468 | −4% | No | |
|
|
||||||
| Aug. 4, 2026 filed Aug. 1, 2026 | Christmas Patrick J. Chief Strategy & Legal Officer | $45,533 | 4,699 | −2% | No | |
|
|
||||||
| July 6, 2026 filed Dec. 31, 2025 | Simpson Curran Chief Executive Officer | −$57,779 | 9,222 | −1% | No | |
|
|
||||||
Showing the 5 most recent of 7 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free